Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Pharma Gmbh & Co Kg

Boehringer Ingelheim Pharma Kg

Boehringer Ingelheim International Pharma Gmbh & Co. Kg

Flavio Solca

Frank Himmelsbach

Birgit Jung

Anke Baum

Elke Langkopf

Martin Steegmaier

Stefan Matthias Blech

Matthias Grauert

Matthias Hoffmann

Jens Juergen Quant

Gisela Schnapp

Jacobus C A Van Meel

Stephan Karl Zahn

Florian Colbatzky

Christian Eickmeier

Harald Engelhardt

Heinz Stadtmueller

Ulrich Reiser

Gerd Stehle

Thomas Metz

Guido Boehmelt

Ulrich Guertler

Andree Amelsberg

Jacobus C Van Meel

Steffen Breitfelder

Trixi Brandl

Andreas Schoop

Matthias Treu

Norbert Redemann

Frank Hilberg

Ulrike Tontsch-Grunt

Jens Jurgen Quant

Jacobus Ca Van Meel

Thorsten Lehmann-Lintz

Rudolf Hauptmann

Andreas Mantoulidis

Robert Michael Lorence

Bodo Betzemeier

Otmar Schaaf

Daniel Kuhn

Oliver Kraemer

Gerd Michael Munzert

Marco Hans Hofmann

Matthias Hoffman

Bojan Bister

Thomas Karner

Markus Reschke

Lars Herfurth

Louis Denis

Mehdi Shahidi

Jacobus CA Van Meel

Stephan Zahn

Martin Friedrich Stefanic

Stefan Blech

Jens Quant

The invention relates to the combined use of certain bispecific, VEGF and Ang2 binding molecules with PD1 antagonists for the treatment of cancer. It further relates to pharmaceutical compositions and kits comprising such binding molecules and antagonists.

Anti-cancer combination therapy

The present invention relates to the use of quinazolines of formula (I), wherein the groups Rto Rhave the meanings given in the claims and specification, in cancer therapy.

Quinazoline derivatives for the treatment of cancer diseases

The present invention relates to a method of treatment of patients suffering from cancer and harboring mutations of EGFR in the tumor, for instance an activating mutation of the EGFR or a mutation responsible for resistance or the emergence of acquired resistance to treatment with reversible EGFR and/or HER2 inhibitors or irreversible inhibitors such as CI-1033, EKB-569, HKI-272 or HKI-357, comprising administering an effective amount of the irreversible EGFR inhibitor BIBW2992 (1) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline, to a person in need of such treatment, optionally in combination with the administration of a further chemotherapeutic agent, in combination with radiotherapy, radio-immunotherapy and/or tumor resection by surgery, and to the use of a BIBW 2992 (1) for preparing a pharmaceutical composition for the treatment of patients suffering from cancer and harboring mutations of EGFR in the tumor.

Method for treating cancer harboring EGFR mutations

The present invention relates to a method of treating patients suffering from cancers driven by deregulated Human Epidermal Growth Factor Receptor (HER/Human EGFR), wherein an irreversible tyrosine kinase inhibitor (TKI) is administered according to a continuous regimen based on an average daily dose in the range of 10 to 50 mg and the mAB is co-administered according to a dosing regimen ranging from an average weekly iv dose of 50 to 500 mg/mrepeated thrice, twice or once a week, once in two weeks, once in three weeks or at least monthly to a patient in need of such treatment.

Method for EGFR directed combination treatment of non-small cell lung cancer

The present invention relates to bicyclic heterocycles of general formula wherein

Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them

The present invention encompasses compounds of general formula (1) wherein

Compounds

Quinazoline derivatives and pharmaceutical compositions containing them

The present invention relates to the use of quinazolines of formula (I), wherein the groups Rto Rhave the meanings given in the claims and specification, in cancer therapy. 

The present invention relates methods for treating disease conditions selected from the list consisting of benign or malignant tumors, diseases of the airways and lungs, diseases of the gastrointestinal tract, the bile duct and the gall bladder by administration to a patient in need thereof of a therapeutically effective amount of a bicyclic heterocyclic groups of general formula wherein said substituents are as defined herein.

Bicyclic heterocyclic compounds pharmaceutical compositions containing these compounds, their use and process for preparing the same

The present invention encompasses compounds of general Formula (1) wherein R, R, Q, W, X, Y and Z are defined as in claim, which are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties. 

Substituted indolines as tyrosine kinase inhibitors

Disclosed are new dihydropteridinones of general formula (I) wherein the groups L and R-Rhave the meanings given in the claims and specification, the isomers thereof, intermediates and processes for preparing these dihydropteridinones and the use thereof as pharmaceutical compositions.

Dihydropteridinone compounds

Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them

The present invention relates to bicyclic heterocycles of general formula whereinR, R, R, A, B, C, D, E and X are defined as in claim, the tautomers, the stereoisomers, the mixtures and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids which have valuable pharmacological properties, particularly an inhibitory effect on signal transduction mediated by tyrosine kinases, the use thereof for treating diseases, particularly tumoral diseases, as well as benign prostatic hyperplasia (BPH), diseases of the lungs and respiratory tract, and the preparation thereof.

Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof

Growing community of inventors

Vienna, Austria

Flavio Solca